Cutera (CUTR) Receiving Somewhat Favorable News Coverage, Report Finds
News coverage about Cutera (NASDAQ:CUTR) has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cutera earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 45.4628641093367 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of research firms recently commented on CUTR. Maxim Group reiterated a “hold” rating on shares of Cutera in a report on Wednesday, November 8th. Zacks Investment Research cut Cutera from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Roth Capital lifted their price target on Cutera from $41.00 to $47.00 and gave the stock a “buy” rating in a report on Tuesday, September 12th. TheStreet upgraded Cutera from a “c” rating to a “b” rating in a report on Friday, August 18th. Finally, BidaskClub upgraded Cutera from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Cutera currently has an average rating of “Buy” and an average target price of $37.33.
Shares of Cutera (CUTR) traded up $1.10 during mid-day trading on Friday, reaching $40.60. 218,500 shares of the company’s stock traded hands, compared to its average volume of 144,469. The firm has a market capitalization of $547.27, a P/E ratio of 50.64, a PEG ratio of 1.71 and a beta of 0.53. Cutera has a 1 year low of $16.25 and a 1 year high of $47.15.
Cutera (NASDAQ:CUTR) last issued its quarterly earnings data on Tuesday, November 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.34. The firm had revenue of $38.17 million during the quarter, compared to the consensus estimate of $34.82 million. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The business’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same period last year, the business posted $0.12 earnings per share. research analysts expect that Cutera will post 0.55 earnings per share for the current year.
In other news, CFO Ronald J. Santilli sold 5,775 shares of Cutera stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $40.43, for a total value of $233,483.25. Following the completion of the sale, the chief financial officer now directly owns 50,012 shares in the company, valued at $2,021,985.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $38.45, for a total transaction of $38,450.00. The disclosure for this sale can be found here. Insiders have sold 20,725 shares of company stock valued at $843,253 over the last 90 days. Company insiders own 11.60% of the company’s stock.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.